title: The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
abstract: Cell lines have been used for drug discovery as useful models of cancers; however, they do not recapitulate cancers faithfully, particularly from the viewpoints of microenvironmental independence. Patient-derived xenografts (PDX) are established by the transfer of primary tumor cells directly from patients into immunodeficient mice and can provide primary-like tumor cells of the amount needed at the desired time. We developed a high-throughput drug screening system using PDX cells and performed drug screening using the PDX cells of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). We established four Ph+ ALL PDX mice and performed high-throughput screening of 3440 compounds using leukemia cells from the PDX mice (PDX-cell screening). The profiles of drugs selected by PDX-cell screening were markedly different from those by screening using the Ph+ ALL cell line. We found that verteporfin, an FDA-approved drug, exhibited strong PDX cell-specific cytotoxicity. In the validation assay, its GI50 was 228 nM, 395 nM, and 538 nM in three PDX cells and 3.93 µM, 2.11 µM, and 5.61 µM in three cell lines. Although verteporfin is a photosensitizer activated by photoirradiation, its cytotoxic effects were mediated by the light-independent production of reactive oxygen species; therefore, its anti-leukemic effects were also exerted in vivo without photoirradiation. Furthermore, it exhibited synergistic effects with dasatinib, an ABL kinase inhibitor. These results indicated the potential of verteporfin as a new anti-leukemic reagent.
authors: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors: Takanobu
authors: T
authors: Morishita
authors: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors: Fumihiko
authors: F
authors: Hayakawa
authors: Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd., Otsu, Japan.
authors: Keiki
authors: K
authors: Sugimoto
authors: Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
authors: Mizuho
authors: M
authors: Iwase
authors: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors: Hideyuki
authors: H
authors: Yamamoto
authors: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors: Daiki
authors: D
authors: Hirano
authors: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors: Yuki
authors: Y
authors: Kojima
authors: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors: Naoto
authors: N
authors: Imoto
authors: National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
authors: Tomoki
authors: T
authors: Naoe
authors: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors: Hitoshi
authors: H
authors: Kiyoi
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D000069439:Dasatinib / Q000494:pharmacology* / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004357:Drug Synergism; D006801:Humans; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D010677:Philadelphia Chromosome; D017319:Photosensitizing Agents / Q000494:pharmacology* / Q000627:therapeutic use; D011166:Porphyrins / Q000494:pharmacology* / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors; D017382:Reactive Oxygen Species / Q000378:metabolism; D000077362:Verteporfin; D023041:Xenograft Model Antitumor Assays
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D047428:Protein Kinase Inhibitors; D017382:Reactive Oxygen Species; D000077362:Verteporfin; D016315:Proto-Oncogene Proteins c-abl; D000069439:Dasatinib
keywords: Ph+ ALL; drug repositioning; drug screening; patient-derived xenograft; verteporfin